Novo Nordisk’s Etavopivat Meets Phase 3 Endpoints in Sickle Cell Disease
Novo Nordisk announced topline findings from HIBISCUS, a pivotal Phase 3 study evaluating once-daily oral etavopivat in adults and adolescents living with Sickle Cell Disease. The trial met both co-primary endpoints, with etavopivat showing significant reductions in vaso-occlusive crises (VOCs) and notable improvements in haemoglobin (Hb) response compared with placebo.
Etavopivat, a once-daily oral pyruvate kinase-R (PKR) activator, is being developed as a potential treatment for Sickle Cell Disease, a severe, life-threatening condition affecting an estimated 8 million people globally.
...
